A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Lung Cancer
- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- September 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
Florida · 1
- University of Miami Hospital and Clinics, Sylvester Cancer Center · Miami, FL
New Jersey · 1
- John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, NJ
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Oregon · 2
- Providence Portland Medical Center · Portland, OR
- Providence St. Vincent Medical Center · Portland, OR
Tennessee · 1
- University of Tennessee Medical Center · Knoxville, TN
Texas · 1
- NEXT Oncology - Irving · Irving, TX
Washington · 1
- Swedish Medical Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.